43:I[58016,["/_next/static/chunks/b5ea50e123aa84a6.js","/_next/static/chunks/050761d0d0bdc5d8.js","/_next/static/chunks/de880ec5a0241b38.js","/_next/static/chunks/48003610e91209eb.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/81ce7bf5f20dbd5a.js","/_next/static/chunks/86498082dde169e6.js","/_next/static/chunks/903c358828afe0bc.js","/_next/static/chunks/f63fb02bc4156bfb.js","/_next/static/chunks/88bed98e5cd5e639.js"],"ProcessEpisodeButton"] 45:I[185,["/_next/static/chunks/b5ea50e123aa84a6.js","/_next/static/chunks/050761d0d0bdc5d8.js","/_next/static/chunks/de880ec5a0241b38.js","/_next/static/chunks/48003610e91209eb.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/81ce7bf5f20dbd5a.js","/_next/static/chunks/86498082dde169e6.js","/_next/static/chunks/903c358828afe0bc.js","/_next/static/chunks/f63fb02bc4156bfb.js","/_next/static/chunks/88bed98e5cd5e639.js"],"SendEmailButton"] 46:I[45269,["/_next/static/chunks/b5ea50e123aa84a6.js","/_next/static/chunks/050761d0d0bdc5d8.js","/_next/static/chunks/de880ec5a0241b38.js","/_next/static/chunks/48003610e91209eb.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/81ce7bf5f20dbd5a.js","/_next/static/chunks/86498082dde169e6.js","/_next/static/chunks/903c358828afe0bc.js","/_next/static/chunks/f63fb02bc4156bfb.js","/_next/static/chunks/88bed98e5cd5e639.js"],"SignupCTA"] 48:I[56939,["/_next/static/chunks/b5ea50e123aa84a6.js","/_next/static/chunks/050761d0d0bdc5d8.js","/_next/static/chunks/de880ec5a0241b38.js","/_next/static/chunks/48003610e91209eb.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/81ce7bf5f20dbd5a.js","/_next/static/chunks/86498082dde169e6.js","/_next/static/chunks/903c358828afe0bc.js","/_next/static/chunks/f63fb02bc4156bfb.js","/_next/static/chunks/88bed98e5cd5e639.js"],"EpisodeTranscript"] 3c:["$","svg",null,{"className":"w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M8 7V3m8 4V3m-9 8h10M5 21h14a2 2 0 002-2V7a2 2 0 00-2-2H5a2 2 0 00-2 2v12a2 2 0 002 2z"}]}] 3d:["$","time",null,{"dateTime":"2025-07-12T13:00:00.000Z","children":"Sat Jul 12 2025"}] 44:T697,

The First AI-Discovered Antifibrotic Drug Enters the Clinic

接着上一期，我们这次来聚焦全球首个真正意义上由生成式 AI 驱动完成“靶点+药物”全流程的真实案例 —— Rentosertib（又名 INS018_055）。

你能想象吗？一款 AI 从头发现、设计并推动进临床的小分子药物，正在给特发性肺纤维化（IPF）患者带来新的希望。🧬💊

由 Insilico Medicine 的 AI 平台开发，这款小分子抑制剂靶向 AI 预测的新靶点 TNIK，在刚发布的 IIa 期临床试验中表现出良好的安全性，并在高剂量组显示出肺功能（FVC）提升近百毫升的趋势。

更令人惊讶的是：从靶点发现到进入临床，仅用不到 30 个月——而传统流程往往耗时 10 年以上。

这不只是 AI 医药的炫技展示，更可能预示一场颠覆现有研发范式的革命。而你，也可能是这场变革的受益者。

AI真的能替科学家造药吗？它是希望，还是风险？听完这集，你或许会对“药物是怎么诞生的”有全新的认识。

📚 引用研究：

Xu, Z. et al. A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nature Medicine, 2025.
Ren, F. et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nature Biotechnology, 2024.
Zitnik, M. AI-enabled drug discovery reaches clinical milestone. Nature Medicine, 2025.

E8 |🧪首个 AI 药物完成二期 IIa 临床试验：Rentosertib 解密